<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04070300</url>
  </required_header>
  <id_info>
    <org_study_id>2018/1592</org_study_id>
    <nct_id>NCT04070300</nct_id>
  </id_info>
  <brief_title>Physical Activity and Ventricular Arrhythmias</brief_title>
  <official_title>Physical Activity and Ventricular Arrhythmias</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Olavs Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Norwegian University of Science and Technology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>St. Olavs Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to determine the effect of aerobic interval training in patients
      with an implantable cardioverter defibrillator (ICD) on physical fitness, quality of life and
      the amount of serious ventricular arrhythmic events on short and long term.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this study, participants will be randomly assigned to either take part in the exercise
      program or serve as control and live as usual. At baseline study visit, study researchers
      will review medical records to collect various information, including the reason for needing
      an ICD, the type and settings of the ICD, medication use and medical history etc. All
      participants will undergo blood collection, complete a questionnaire to assess quality of
      life and undergo examination with echocardiography and ECG. The ICD will be programmed
      accordingly to international guidelines regarding ICD-therapy and optimal monitoring, before
      each participant complete an exercise treadmill test to determine VO2 peak. They will wear a
      Holter monitor to record heart activity 48 hours before the test and 24 hours after the test.
      All participants will then be observed for 2 months before being randomly assigned to either
      intervention or control. During this observation period, they will wear a fitness activity
      tracker wristband to evaluate degree of physical activity and a Holter monitor to register
      number of premature ventricular contractions. Participants taking part in the interval
      training group will perform aerobic interval training 4 x 4 minutes intervals, 3 times a week
      for 12 weeks (week 1-12), whereas participants taking part in the control group will carry on
      with usual daily life with no lifestyle recommendations. All participants will then undergo a
      new period of observation (week 13-20) and repeat the tests and examinations performed at
      baseline and during the observation period prior to intervention/control.
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">September 2, 2019</start_date>
  <completion_date type="Anticipated">May 2022</completion_date>
  <primary_completion_date type="Anticipated">May 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in physical fitness/aerobic capacity</measure>
    <time_frame>Change from baseline and after ended intervention period (12 weeks)</time_frame>
    <description>Expressed in and measured with maximal oxygen uptake (VO2 peak)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in assessment of quality of life</measure>
    <time_frame>Change from baseline and after intervention period (12 weeks)</time_frame>
    <description>Patient-reported survey of patient health SF-36</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in burden of ventricular arrhythmias from baseline to week 9-12</measure>
    <time_frame>Baseline and the last 4 weeks of intervention period (week 9-12)</time_frame>
    <description>Evaluated by number of ICD discharges (registered on ICD)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in burden of ventricular arrhythmias from baseline to week 13-16</measure>
    <time_frame>Baseline and the first 4 weeks after intervention period (week 13-16)</time_frame>
    <description>Evaluated by number of ICD discharges (registered on ICD)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in burden of ventricular arrhythmias from baseline to week 9-16</measure>
    <time_frame>Baseline and the last 4 weeks of intervention period plus 4 first weeks after intervention period (week 9-16)</time_frame>
    <description>Evaluated by number of ICD discharges (registered on ICD)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in burden of ventricular arrhythmias from baseline to week 9-12</measure>
    <time_frame>Baseline and the last 4 weeks of intervention period (week 9-12)</time_frame>
    <description>Evaluated by number of episodes with antitachycardia pacing (registered on ICD)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in burden of ventricular arrhythmias from baseline to week 13-16</measure>
    <time_frame>Baseline and the first 4 weeks after intervention period (week 13-16)</time_frame>
    <description>Evaluated by number of episodes with antitachycardia pacing (registered on ICD)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in burden of ventricular arrhythmias from baseline to week 9-16</measure>
    <time_frame>Baseline and the last 4 weeks of intervention period plus 4 first weeks after intervention period (week 9-16)</time_frame>
    <description>Evaluated by number of episodes with antitachycardia pacing (registered on ICD)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in burden of ventricular arrhythmias from baseline to week 9-12</measure>
    <time_frame>Baseline and the last 4 weeks of intervention period (week 9-12)</time_frame>
    <description>Evaluated by number of episodes with monitored ventricular tachycardias without ICD-therapy (registered on ICD)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in burden of ventricular arrhythmias from baseline to week 13-16</measure>
    <time_frame>Baseline and the first 4 weeks after intervention period (week 13-16)</time_frame>
    <description>Evaluated by number of episodes with monitored ventricular tachycardias without ICD-therapy (registered on ICD)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in burden of ventricular arrhythmias from baseline to week 9-16</measure>
    <time_frame>Baseline and the last 4 weeks of intervention period plus 4 first weeks after intervention period (week 9-16)</time_frame>
    <description>Evaluated by number of episodes with monitored ventricular tachycardias without ICD-therapy (registered on ICD)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in burden of ventricular arrhythmias from baseline to week 9-12</measure>
    <time_frame>Baseline and the last 4 weeks of intervention period (week 9-12)</time_frame>
    <description>Evaluated by number of premature ventricular contractions (registered on a 72 hours Holter monitoring)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in burden of ventricular arrhythmias from baseline to week 13-16</measure>
    <time_frame>Baseline and the first 4 weeks after intervention period (week 13-16)</time_frame>
    <description>Evaluated by number of premature ventricular contractions (registered on a 72 hours Holter monitoring)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in burden of ventricular arrhythmias from baseline to week 9-16</measure>
    <time_frame>Baseline and the last 4 weeks of intervention period plus 4 first weeks after intervention period (week 9-16)</time_frame>
    <description>Evaluated by number of premature ventricular contractions (registered on a 72 hours Holter monitoring)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac function</measure>
    <time_frame>Baseline and after ended intervention period (12 weeks)</time_frame>
    <description>Evaluated by changes in left ventricular dimensions and systolic/diastolic function assessed by echocardiography and blood values (NT-proBNP and troponin T)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in degree of physical activity</measure>
    <time_frame>Baseline and after ended intervention period (12 weeks)</time_frame>
    <description>Assessed by number of steps daily registered with fitness activity tracker wristband (worn for 1 week)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in adiposity</measure>
    <time_frame>Baseline and after ended intervention period (12 weeks)</time_frame>
    <description>Evaluated by changes in waist circumference (cm) and BMI (kg/m^2) as measures of adiposity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in cholesterol value</measure>
    <time_frame>Baseline and after ended intervention period (12 weeks)</time_frame>
    <description>Evaluated by changes in total cholesterol, HDL-cholesterol, LDL-cholesterol (all in mmol/L) as a measure of cardiac risk</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in triglycerides value</measure>
    <time_frame>Baseline and after ended intervention period (12 weeks)</time_frame>
    <description>Evaluated by changes in triglycerides ( in mmol/L) as a measure of cardiac risk</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in heart rate variability</measure>
    <time_frame>Baseline and after ended intervention period (12 weeks)</time_frame>
    <description>Evaluated by measuring changes in SDNN, SDANN 5, ASDNN 5 and RMSSD registered on a 72 hours Holter monitoring</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in number of premature ventricular contractions during a single bout of high intensity exercise (VO2 peak test)</measure>
    <time_frame>Baseline and after ended intervention period (12 weeks)</time_frame>
    <description>Measured by changes in the number of premature ventricular contractions during VO2 peak testing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in signal-averaged ECG (SA-ECG)</measure>
    <time_frame>Baseline and after ended intervention period (12 weeks)</time_frame>
    <description>Measured by quantifying late potentials after depolarization of the ventricles</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Tachycardia, Ventricular</condition>
  <condition>Defibrillators, Implantable</condition>
  <arm_group>
    <arm_group_label>Interval training group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Aerobic interval training during 12 weeks 3 times a week.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No lifestyle recommendations. Usual daily life.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Interval exercise</intervention_name>
    <description>Aerobic interval training during 12 weeks 3 times a week: 4 x 4 minutes intervals at an intensity of 90-95% of VO2 peak and active breaks of 3 minutes between intervals.</description>
    <arm_group_label>Interval training group</arm_group_label>
    <other_name>interval training</other_name>
    <other_name>aerobic exercise training</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with ICD and dilated cardiomyopathy or coronary heart disease as cause for
             implantation

          -  ICD implanted at St Olavs hospital, Trondheim

        In case of difficulties with patient inclusion for the study, the criteria might be
        broadened to include patients with idiopathic ventricular arrhythmia as cause for
        implantation.

        Exclusion Criteria:

          -  inability to accomplish the exercise program due to serious comorbidity or to
             participate in regular training within the next 3 months due to other reasons

          -  signs of severe cardiac ischemia or persistent ventricular tachycardia during
             individualized treadmill O2 peak test, which after individual assessment is to be
             found at risk

          -  comorbidity where endurance training at more than moderate intensity is discouraged

          -  severe cardiac valve disease

          -  planned surgery within the next 3 months

          -  inability to give informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rune Wiseth, MD, Prof</last_name>
    <role>Study Director</role>
    <affiliation>St. Olavs Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St Olavs Hospital</name>
      <address>
        <city>Trondheim</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>August 21, 2019</study_first_submitted>
  <study_first_submitted_qc>August 26, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 28, 2019</study_first_posted>
  <last_update_submitted>October 8, 2019</last_update_submitted>
  <last_update_submitted_qc>October 8, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 9, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Exercise Training</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tachycardia</mesh_term>
    <mesh_term>Tachycardia, Ventricular</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Individual participant data for all primary and secondary outcome measures will be made available after deidentiÔ¨Åcation and publication</ipd_description>
    <ipd_time_frame>After publication</ipd_time_frame>
    <ipd_access_criteria>Not yet decided</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

